SCHEMBL13823410

SCHEMBL13823410

C=C(C)c1cc(NC(=O)CNc2ccc(Oc3ccncc3)cc2)on1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 7/20 0.50
RIPK2 O43353 1/20 0.43
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
GRK2 P25098 4/20 0.40
GRK3 P35626 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
ROCK2 O75116 1/20 0.40
KMT2A Q03164 1/20 0.40
NLRP1 Q9C000 1/20 0.40
GALR3 O60755 1/20 0.38
GAA P10253 1/20 0.38
ACACB O00763 1/20 0.38
MMP1 P03956 1/20 0.37
NPY5R Q15761 1/20 0.36
MAPK13 O15264 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13972318 0.83 RAF1 (0.48) RAF1RIPK2GRK2GRK3ALDH1A1
SCHEMBL4441367 0.83 RAF1 (0.73) RAF1RIPK2ADORA3ADORA2AADORA2B
SCHEMBL14136181 0.78 RAF1 (0.50) RAF1RIPK2GRK2GRK3ALDH1A1
SCHEMBL4444438 0.75 RAF1 (0.72) RAF1RIPK2MAPK13
SCHEMBL13823425 0.73 GRK2 (0.53) RAF1RIPK2GRK2GRK3ROCK2
SCHEMBL4442571 0.73 RAF1 (0.62) RAF1RIPK2GRK2GRK3ROCK2
SCHEMBL14402898 0.69 RAF1 (0.48) RAF1RIPK2ROCK2KMT2A
SCHEMBL937763 0.68 RAF1 (0.70) RAF1RIPK2ALDH1A1MAPK13
SCHEMBL937764 0.67 RAF1 (0.66) RAF1RIPK2MAPTMAPK13
SCHEMBL667897 0.67 RAF1 (1.00) RAF1RIPK2ALDH1A1MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163556-A1 GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS BUCHSTALLER HANS-PETER 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163556-A1 GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS ARAF, BRAF, RAF1 RAF1 3/4885RIPK2 491/4885ADORA3 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.